INVESTABOT
Equity Research
XNYS · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
Medtronic (MDT) had 1 Form 144 pre-sale notice filed on 2026-09-16. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Medtronic (MDT) had 1 Form 144 pre-sale notice filed on 2026-07-08. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one filing…
Medtronic (MDT) had 1 Form 144 pre-sale notice filed on 2026-06-08. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
TL;DR: Medtronic posted Q4 revenue of $9.8 billion, up 9.9% from $8.93 billion a year ago, beating its own implied guidance by 90 basis points. The results cap what the company calls its strongest annual revenue growth…
TL;DR: Medtronic filed an officer change disclosure on May 18, 2026, but the available filing text does not identify the executive involved or the nature of the change. Without a named individual or stated role, the…
open-market Form 4 only - grants, exercises, tax withholding excluded
0 buyers - 2 unique sellers · 10 accumulating - 3 trimming - 1 unchanged
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| September 16, 2026 | Kiil Harry Skip | EVP & President Cardiovascular | SELL | -1,483 | $94 | ~$0.1M |
| September 15, 2026 | Blomquist Denise L. | Chief Accounting Officer | GIFT | -600 | — | — |
| August 20, 2026 | Marinaro Michael | EVP, Pres MedSurg and Americas | TAX_WITHHOLD | -1,084 | $92 | ~$0.1M |
| August 3, 2026 | Blomquist Denise L. | Chief Accounting Officer | GRANT | 2,337 | — | — |
| August 3, 2026 | Blomquist Denise L. | Chief Accounting Officer | GRANT | 1,366 | — | — |
| August 3, 2026 | Walter Matthew R. | SVP, Chief HR Officer | GRANT | 5,769 | — | — |
| August 3, 2026 | Walter Matthew R. | SVP, Chief HR Officer | GRANT | 14,421 | — | — |
| August 3, 2026 | Walter Matthew R. | SVP, Chief HR Officer | GRANT | 40,973 | — | — |
| August 3, 2026 | Thompson Kweli | EVP & President, Neuroscience | GRANT | 6,923 | — | — |
| August 3, 2026 | Thompson Kweli | EVP & President, Neuroscience | GRANT | 17,306 | — | — |
| August 3, 2026 | Thompson Kweli | EVP & President, Neuroscience | GRANT | 49,167 | — | — |
| August 3, 2026 | Quinn Michelle | EVP, GC and Secretary | GRANT | 6,346 | — | — |
| August 3, 2026 | Quinn Michelle | EVP, GC and Secretary | GRANT | 15,863 | — | — |
| August 3, 2026 | Quinn Michelle | EVP, GC and Secretary | GRANT | 45,070 | — | — |
| August 3, 2026 | Pieton Thierry | EVP & Chief Financial Officer | GRANT | 11,537 | — | — |
| August 3, 2026 | Pieton Thierry | EVP & Chief Financial Officer | GRANT | 28,842 | — | — |
| August 3, 2026 | Pieton Thierry | EVP & Chief Financial Officer | GRANT | 81,945 | — | — |
| August 3, 2026 | Marinaro Michael | EVP, Pres MedSurg and Americas | GRANT | 10,960 | — | — |
| August 3, 2026 | Marinaro Michael | EVP, Pres MedSurg and Americas | GRANT | 46,147 | — | — |
| August 3, 2026 | Marinaro Michael | EVP, Pres MedSurg and Americas | GRANT | 27,400 | — | — |
| Date | Insider | Title | Relationship | Shares | Filing |
|---|---|---|---|---|---|
| June 26, 2026 | — | — | — | — | SEC |
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| Vanguard Group | 128,961,343 | ~$12.4B | — | January 29, 2026 |
| BlackRock | 120,537,878 | ~$11.6B | — | February 12, 2026 |
| BlackRock | 113,182,567 | ~$9.8B | -6.1% | May 13, 2026 |
| BlackRock | 114,020,787 | ~$8.9B | 0.7% | August 7, 2026 |
| BlackRock | 111,892,378 | ~$8.8B | — | August 13, 2024 |
| State Street | 61,660,158 | ~$6.0B | — | February 13, 2026 |
| State Street | 61,741,014 | ~$5.4B | 0.1% | May 15, 2026 |
| JP Morgan Chase | 53,616,694 | ~$5.2B | — | February 11, 2026 |
| State Street | 63,399,315 | ~$5.0B | 2.7% | August 7, 2026 |
| JP Morgan Chase | 51,058,541 | ~$4.4B | -4.8% | May 13, 2026 |
| JP Morgan Chase | 27,878,171 | ~$2.3B | -45.4% | August 12, 2026 |
| Morgan Stanley | 20,222,575 | ~$1.9B | — | May 27, 2026 |
| Morgan Stanley | 20,717,029 | ~$1.8B | 2.5% | May 15, 2026 |
| Morgan Stanley | 19,444,871 | ~$1.5B | -6.1% | August 13, 2026 |
| Goldman Sachs | 9,012,210 | ~$705.0M | 57.0% | August 14, 2026 |
| Citadel Advisors | 7,201,188 | ~$691.7M | — | February 17, 2026 |
| Citadel Advisors | 7,784,077 | ~$608.9M | 173.4% | August 14, 2026 |
| Goldman Sachs | 6,220,848 | ~$597.6M | — | March 25, 2026 |
| Goldman Sachs | 5,740,590 | ~$497.4M | -7.7% | May 15, 2026 |
| Millennium Management | 4,604,488 | ~$442.3M | — | February 17, 2026 |